Intelligence Β· Clinical Pipeline

Kailera Therapeutics Pipeline

All ClinicalTrials.gov programs at Kailera Therapeutics β€” phase, modality, and trial IDs.

Programs
9

Quick answer

Kailera Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Dextromethorphan HBr

    Galera Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial
  2. GC4419

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  3. GC4419

    Galera Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  4. GC4419

    Galera Therapeutics

    Squamous Cell Carcinoma of the Oral Cavity

    phase 1 small molecule completed

    1 trial
  5. GC4419 IV

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  6. GC4702 dry powder

    Galera Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial
  7. GC4711 30 mg IV

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  8. GC4711 30mg

    Galera Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial
  9. GC4711 Oral Capsule G-101

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Kailera Therapeutics have?

9 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs